|Bid||25.62 x 800|
|Ask||25.64 x 900|
|Day's Range||24.95 - 25.73|
|52 Week Range||13.87 - 69.57|
|Beta (3Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hatteras Venture Partners has taken big risks in seed-level investing on early-stage life pharmaceutical, but it looks to be paying off – at least for now.
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
Three biotechnology companies, along with recent IPO Pinterest, are among our four charts to watch today. G1 Therapeutics Inc. (GTHX) jumped $4.75, or 24%, to $24.50 on 2.2 million shares traded Tuesday. The move, on over five times its average volume, came on news of encouraging data from the company’s Phase II study of its trilaciclib treatment for metastatic triple-negative breast cancer.
New clinical data out a recent cancer study spells good news for a Triangle drugmaker, as well as patients who could see longer lives thanks to its product.
Shares of G1 Therapeutics Inc (NASDAQ: GTHX ) were advancing strongly on above-average volume Tuesday in reaction to a clinical trial readout. What Happened Oncology biotech G1 announced preliminary overall ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
"Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
Sailing toward a new drug application on a wave of positive data and skyrocketing stocks, one Triangle public company says it will also be bringing more hands on board.
Shares of G1 Therapeutics Inc (NASDAQ: GTHX ), an oncology biotech, have climbed to their highest level so far in 2019, courtesy of an announcement from the company regarding trilaciclib, its investigational ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
G1 Therapeutics Inc. shares skyrocketed 25% in the extended session Monday after the company said it expects to file a new-drug application for its trilaciclib, a drug designed to protect bone marrow from the effects of chemotherapy. That's based on feedback from a meeting with the U.S. Food and Drug Administration and discussion with European regulators, G1 said in a statement. "We look forward to continuing a collaborative dialogue regarding the marketing applications, as well as discussing further clinical development of trilaciclib," Chief Medical Officer Raj Malik said in the statement. Chemotherapy is an effective and important weapon against cancer, but it does not differentiate between healthy cells and cancer cells and kills both, including important stem cells in the bone marrow; trilaciclib has demonstrated in trials the ability to protect bone marrow from chemotherapy damage, the company said in the statement. Shares of G1 ended the regular trading day down 0.2%.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
G1 THERAPEUTICS (GTHX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.